The ascendancy of Viagra and its impact on the medicinal landscape presents a intricate question for shareholders. While the first sales data were remarkable, the exclusivity has expired, leading to a wave of generic alternatives that are chipping away at profit. Moreover, the industry is facing difficulties related to population trends and changin